Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$6.14 ▼ -0.15
(-2.46%)
MKT CAP: $652.8M • VOL: 533.0K
52W L $5 52W H $10
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$5
MEDIAN
$7
MEAN
$7
HIGH
$8
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AURA TAPE
AURA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $7.43 | $7.06 | 2025-02-14 | $5.59 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $7.74 | $7.25 | 2025-02-06 | $5.77 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $7.00 | $6.75 | 2025-01-29 | $5.89 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $6.26 | — | 2025-01-17 | $6.02 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $5.40 | $5.83 | 2025-01-09 | $5.46 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $7.31 | $6.39 | 2024-12-18 | $5.34 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $5.96 | $6.20 | 2024-12-04 | $5.71 | -4.3% | 48% | C |